PL394082A1 - Liposomowy preparat zawierający przeciwnowotworową substancję aktywną, sposób jego wytwarzania i zawierająca go kompozycja farmaceutyczna - Google Patents

Liposomowy preparat zawierający przeciwnowotworową substancję aktywną, sposób jego wytwarzania i zawierająca go kompozycja farmaceutyczna

Info

Publication number
PL394082A1
PL394082A1 PL394082A PL39408211A PL394082A1 PL 394082 A1 PL394082 A1 PL 394082A1 PL 394082 A PL394082 A PL 394082A PL 39408211 A PL39408211 A PL 39408211A PL 394082 A1 PL394082 A1 PL 394082A1
Authority
PL
Poland
Prior art keywords
preparation
pharmaceutical composition
active substance
composition containing
cancer active
Prior art date
Application number
PL394082A
Other languages
English (en)
Other versions
PL226015B1 (pl
Inventor
Jerzy Gubernator
Arkadiusz Kozubek
Piotr Paduszyński
Original Assignee
Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną Odpowiedzialnością
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną Odpowiedzialnością filed Critical Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną Odpowiedzialnością
Priority to PL394082A priority Critical patent/PL226015B1/pl
Priority to JP2013555988A priority patent/JP2014506918A/ja
Priority to CN2012800113206A priority patent/CN103415283A/zh
Priority to CA2828971A priority patent/CA2828971A1/en
Priority to AU2012222891A priority patent/AU2012222891A1/en
Priority to ES12719451T priority patent/ES2703750T3/es
Priority to US14/002,558 priority patent/US20140056968A1/en
Priority to PCT/IB2012/051014 priority patent/WO2012117385A2/en
Priority to EP12719451.2A priority patent/EP2680821B1/en
Publication of PL394082A1 publication Critical patent/PL394082A1/pl
Publication of PL226015B1 publication Critical patent/PL226015B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL394082A 2011-03-03 2011-03-03 Liposomowy preparat zawierajacy przeciwnowotworowa substancje aktywna, sposob jego wytwarzania i zawierajaca go kompozycja farmaceutyczna PL226015B1 (pl)

Priority Applications (9)

Application Number Priority Date Filing Date Title
PL394082A PL226015B1 (pl) 2011-03-03 2011-03-03 Liposomowy preparat zawierajacy przeciwnowotworowa substancje aktywna, sposob jego wytwarzania i zawierajaca go kompozycja farmaceutyczna
JP2013555988A JP2014506918A (ja) 2011-03-03 2012-03-03 抗腫瘍活性物質を含むリポソーム製剤、その調製のための方法、及び、それを含む医薬組成物
CN2012800113206A CN103415283A (zh) 2011-03-03 2012-03-03 包含抗肿瘤活性物质的脂质体制剂、它的制备方法以及包含它的药物组合物
CA2828971A CA2828971A1 (en) 2011-03-03 2012-03-03 Liposome formulation comprising an anti-tumour active substance, method for its preparation and pharmaceutical compositions comprising it
AU2012222891A AU2012222891A1 (en) 2011-03-03 2012-03-03 Liposome formulation comprising an anti-tumour active substance, method for its preparation and pharmaceutical compositions comprising it
ES12719451T ES2703750T3 (es) 2011-03-03 2012-03-03 Formulación liposomal que contiene un compuesto activo antitumoral, método para producirla y composiciones farmacéuticas que la contiene
US14/002,558 US20140056968A1 (en) 2011-03-03 2012-03-03 Liposome formulation comprising an anti-tumour active substance, method for its preparation and pharmaceutical compositions comprising it
PCT/IB2012/051014 WO2012117385A2 (en) 2011-03-03 2012-03-03 Liposome formulation comprising an anti-tumour active substance, method for its preparation and pharmaceutical compositions comprising it
EP12719451.2A EP2680821B1 (en) 2011-03-03 2012-03-03 Liposome formulation comprising an anti-tumour active substance, method for its preparation and pharmaceutical compositions comprising it

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL394082A PL226015B1 (pl) 2011-03-03 2011-03-03 Liposomowy preparat zawierajacy przeciwnowotworowa substancje aktywna, sposob jego wytwarzania i zawierajaca go kompozycja farmaceutyczna

Publications (2)

Publication Number Publication Date
PL394082A1 true PL394082A1 (pl) 2012-09-10
PL226015B1 PL226015B1 (pl) 2017-06-30

Family

ID=46045037

Family Applications (1)

Application Number Title Priority Date Filing Date
PL394082A PL226015B1 (pl) 2011-03-03 2011-03-03 Liposomowy preparat zawierajacy przeciwnowotworowa substancje aktywna, sposob jego wytwarzania i zawierajaca go kompozycja farmaceutyczna

Country Status (9)

Country Link
US (1) US20140056968A1 (pl)
EP (1) EP2680821B1 (pl)
JP (1) JP2014506918A (pl)
CN (1) CN103415283A (pl)
AU (1) AU2012222891A1 (pl)
CA (1) CA2828971A1 (pl)
ES (1) ES2703750T3 (pl)
PL (1) PL226015B1 (pl)
WO (1) WO2012117385A2 (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6564873B2 (ja) * 2015-11-02 2019-08-21 富士フイルム株式会社 リポソーム組成物およびその製造方法
WO2019160735A1 (en) * 2018-02-14 2019-08-22 L.E.A.F. Holdings Group Llc Gamma polyglutamated tetrahydrofolates and uses thereof

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
EP0016286B1 (en) * 1979-03-21 1983-04-06 DAVY McKEE (LONDON) LIMITED Hydroformylation process
US4522803A (en) 1983-02-04 1985-06-11 The Liposome Company, Inc. Stable plurilamellar vesicles, their preparation and use
US5169637A (en) 1983-03-24 1992-12-08 The Liposome Company, Inc. Stable plurilamellar vesicles
US5030453A (en) 1983-03-24 1991-07-09 The Liposome Company, Inc. Stable plurilamellar vesicles
JPS60231608A (ja) * 1984-04-28 1985-11-18 Terumo Corp 膜構造が強化されたリポソ−ム
US5008050A (en) 1984-06-20 1991-04-16 The Liposome Company, Inc. Extrusion technique for producing unilamellar vesicles
US4975282A (en) 1985-06-26 1990-12-04 The Liposome Company, Inc. Multilamellar liposomes having improved trapping efficiencies
CA1338702C (en) 1987-03-05 1996-11-12 Lawrence D. Mayer High drug:lipid formulations of liposomal- antineoplastic agents
IL91664A (en) 1988-09-28 1993-05-13 Yissum Res Dev Co Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5527528A (en) 1989-10-20 1996-06-18 Sequus Pharmaceuticals, Inc. Solid-tumor treatment method
CA2088975A1 (en) 1990-08-08 1992-02-09 Anthony H. Huang Stable doxorubicin/liposome composition
EP0546951A1 (en) 1991-12-13 1993-06-16 The Liposome Company, Inc. Combination of liposome encapsulated antineoplastic agents, such as doxorubicin with colony stimulating factors
EP0706373B1 (en) 1992-03-23 2000-07-19 Georgetown University Liposome encapsulated taxol and a method of using the same
JPH06254379A (ja) 1993-03-08 1994-09-13 Taisho Pharmaceut Co Ltd 安定なリポソーム水懸濁液
US5776488A (en) * 1994-03-11 1998-07-07 Yoshitomi Pharmaceutical Industries, Ltd. Liposome preparation
DE4432378A1 (de) * 1994-09-12 1996-03-14 Bayer Ag Injizierbare liposomale Arzneizubereitungen
US5580899A (en) 1995-01-09 1996-12-03 The Liposome Company, Inc. Hydrophobic taxane derivatives
US6262054B1 (en) * 1996-02-01 2001-07-17 Sloan-Kettering Institute Of Cancer Research Combination therapy method for treating breast cancer using edatrexate
US5919815A (en) 1996-05-22 1999-07-06 Neuromedica, Inc. Taxane compounds and compositions
US6090407A (en) 1997-09-23 2000-07-18 Research Development Foundation Small particle liposome aerosols for delivery of anti-cancer drugs
US6146659A (en) * 1998-07-01 2000-11-14 Neopharm, Inc. Method of administering liposomal encapsulated taxane
PL190078B1 (pl) 1998-08-24 2005-10-31 Inst Farmaceutyczny Liposomowy preparat mitoksantronu, sposób jego wytwarzania i przeciwnowotworowa kompozycja farmaceutyczna zawierająca ten preparat
PL190077B1 (pl) 1998-08-24 2005-10-31 Inst Farmaceutyczny Liposomowy preparat doksorubicyny, sposób jego wytwarzania oraz przeciwnowotworowa kompozycja farmaceutyczna zawierająca ten preparat
IL153676A0 (en) 2000-06-30 2003-07-06 Inex Pharmaceuticals Corp Liposomal pharmaceutical compositions
EP1432403B1 (en) * 2001-10-03 2010-07-28 Celator Pharmaceuticals, Inc. Liposome loading with metal ions
US20040176381A1 (en) * 2003-03-06 2004-09-09 Walsh Michael J. Methotrexate compliance packaging
EP1732608A2 (en) * 2004-01-22 2006-12-20 Immunomedics, Inc. Folate conjugates and complexes
JPWO2006088245A1 (ja) * 2005-02-18 2008-07-10 国立大学法人徳島大学 ポリオキシアルキレン鎖含有脂質誘導体及び該誘導体を含有する脂質膜構造体
CN1772303A (zh) * 2005-10-25 2006-05-17 朱宏 恶性肿瘤磁热疗用纳米磁粉－抗体靶向药物
US9017697B2 (en) * 2006-10-12 2015-04-28 The University Of Queensland Compositions and methods for modulating immune responses
US20080206139A1 (en) * 2006-11-03 2008-08-28 The Penn State Research Foundation Delivery system for diagnostic and therapeutic agents
WO2009029543A1 (en) * 2007-08-24 2009-03-05 Aegis Therapeutics, Llc Controlled release formulations

Also Published As

Publication number Publication date
PL226015B1 (pl) 2017-06-30
ES2703750T3 (es) 2019-03-12
AU2012222891A1 (en) 2013-09-19
EP2680821B1 (en) 2018-08-01
US20140056968A1 (en) 2014-02-27
WO2012117385A2 (en) 2012-09-07
CN103415283A (zh) 2013-11-27
WO2012117385A3 (en) 2013-02-28
JP2014506918A (ja) 2014-03-20
CA2828971A1 (en) 2012-09-07
EP2680821A2 (en) 2014-01-08

Similar Documents

Publication Publication Date Title
BR112013030472A2 (pt) formulação farmacêutica, artigo de fabricação e método
BR112012023501A2 (pt) vesículas lipídicas multilamelares, composição farmacêutica e método
BR112013023816A2 (pt) solução ou formulação estabilizada, seu método de preparação, métodos de aplicação e usos
CO6811868A2 (es) Combinaciones de principios activos
BR112012022878A2 (pt) composto, composição farmacêutica, uso do compostos e método de tratamento
EP2762012A4 (en) SMALL MOLECULE ACTIVE DONKEY GELATIN MIXTURE AND PREPARATION METHOD AND APPLICATION THEREOF
BR112014021103A8 (pt) anticorpo, composição farmacêutica, droga de combinação, dna, método de tratamento e uso de anticorpo
BR112014003802A2 (pt) composto, composto composição farmacêutica, uso de um composto, método para fabricar um composto, e, preparação de um medicamento
BR112014009634A2 (pt) preparação e agente terapêutico
CO6880066A2 (es) Composición farmacéutica de sabor enmascarado
BR112013023653A2 (pt) anticorpo biespecífico, método de preparação do anticorpo, e composição farmacêutica
BR112014001346A2 (pt) composto nanotransportador, método, composto farmacêutico e uso de um composto
BR112013011448A2 (pt) composto, composição farnmacêutica, e, uso do composto
BR112014012005A2 (pt) composições, métodos, formulação farmacêutica e artigo
BR112012026570A2 (pt) composto, composição farmacêutica, uso de um composto, método para o tratamento de um indíviduo e produto combinado
BR112014010290A2 (pt) composição farmacêutica, métodos, composições e usos
BR112015004936A2 (pt) composição farmacêutica revestida contendo regorafenib
CO6970609A2 (es) Composición farmacéutica y métodos de uso de derivados de 4-pregenen-11ß-17-21-triol-3,20-diona
BR112014001991A2 (pt) certos inibidores de quinurenina-3-monooxigenase, composições farmacêuticas e métodos de uso dos mesmos
BR112013014644A2 (pt) composição farmacêutica e complexo
BR112012023355A2 (pt) composto, composição farmacêutica e método de ruptura da interação nek2/hec1
BR112013022556A8 (pt) composição farmacêutica aquosa semissólida contendo tapentadol, seu uso e uso de tapentadol
BR112013030644A2 (pt) fosfolipídios contendo ácido(s) nitrocarboxílico(s) da estrutura geral (i), e uso dos mesmos, dispositivo médico e composições biopassivadoras
EP2786982A4 (en) AMINO-PROPYLENE-GLYCOL DERIVATIVES, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF
BR112014006910A2 (pt) composto, substância farmacêutica do composto, método para produzir a substância farmacêutica, uso da substância farmacêutica, método de ensaio de titulação, e, composição farmacêutica e parafarmacêutica